CJA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Résumé de cet Article
Right arrow Full Text (PDF)
Right arrow Submit a scholarly reply
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baxter, A. D.
Right arrow Articles by Jansen, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baxter, A. D.
Right arrow Articles by Jansen, O.
Canadian Journal of Anesthesia 52:535-541 (2005)
© Canadian Anesthesiologists' Society, 2005

Neuroanesthesia and Intensive Care

Adherence to simple and effective measures reduces the incidence of ventilator-associated pneumonia

[L’observation de mesures simples et efficaces réduit l’incidence de pneumonie associée à la ventilation mécanique]

Alan D. Baxter, FRCPC*,{dagger}, Jill Allan, BN{ddagger}, Johane Bedard, BSCN{ddagger}, Sue Malone-Tucker, BSCN{ddagger}, Sharon Slivar, BSCN{ddagger}, Mike Langill, BSCN{ddagger}, Marc Perreault, PHARMD§ and Owen Jansen, BSCN{ddagger}

* From the Departments of Critical Care,
{dagger} Anesthesia,
{ddagger} Nursing, and
§ Pharmacy, The Ottawa Hospital, General Campus, Ottawa, Ontario, Canada.

Address correspondence to: Dr. Alan D. Baxter, Departments of Anesthesia & Critical Care, The Ottawa Hospital, General Campus, 501 Smyth Road, Ottawa, Ontario K1H 8L6, Canada. Phone: 613-737-8187; Fax: 613-737-8189; E-mail: abaxter{at}ottawahospital.on.ca


    Abstract
 TOP
 Abstract
 Introduction
 Methods
 Results
 Discussion
 Conclusion
 References
 
Purpose: Several modalities have been shown to be individually effective in reducing the incidence (and hence associated morbidity, mortality, and costs) of ventilator-associated pneumonia, but their implementation into clinical practice is inconsistent. We introduced an intensive care unit protocol and measured its effect on ventilator-associated pneumonia.

Methods: A multidisciplinary team constructed a multifaceted protocol incorporating low risk and low cost strategies, many of which had independent advantages of their own. Some components were already in use, and their importance was emphasized to improve compliance. New strategies included elevation of the head of the bed, transpyloric enteral feeding, and antiseptic mouthwash. The approach to implementation and maintenance included education, monitoring, audits and feedback to encourage compliance with the protocol.

Results: The implementation of this prevention protocol reduced the incidence of ventilator-associated pneumonia from a baseline of 94 cases per year or 26.7 per 1,000 ventilator days to 51.3 per year or 12.5 per 1,000 ventilator days, i.e., about 50% of the pre-protocol rate (P < 0.0001).

Conclusion: Adherence to simple and effective measures can reduce the incidence of ventilator-associated pneumonia. The protocol described was inexpensive and effective, and estimated savings are large. Implementation and maintenance of gains require a multidisciplinary approach, with buy-in from all team members, and ongoing monitoring, education, and feedback to the participants.


    Introduction
 TOP
 Abstract
 Introduction
 Methods
 Results
 Discussion
 Conclusion
 References
 
VENTILATOR-ASSOCIATED pneumonia (VAP) is the most common intensive care unit (ICU) nosocomial infection, and its incidence (10–30%)1,2 varies with the type of ICU and patient population. Host risk factors include advanced age, abdominal or thoracic surgery, previous antibiotic therapy, immune compromise, decreased level of consciousness, burns, trauma, central nervous system disease, witnessed aspiration and cardiac or pulmonary disease.2 Crude mortality of VAP is up to 30%,3 with 10% attributable to the pneumonia itself and 20% to the underlying disease. The increased risk of death from VAP was 5.8% in a recent Canadian study, associated with an increased ICU stay of 4.3 days.4 Duration of hospital stay is also increased, resulting in increased medical costs.5

Many interventions have been reported to reduce the incidence of VAP, but their implementation is variable,6 and not always sustained. There is potential for producing significant improvement in quality of patient care by effectively using such strategies, with financial savings and improved bed utilization. We therefore undertook a prospective VAP audit, as a quality-of-care indicator, to introduce a protocol of modalities supported by various levels of evidence in an attempt to reduce its apparent high incidence in our multidisciplinary adult ICU. A second goal was to estimate the financial impact of VAP and implementation of the protocol.


    Methods
 TOP
 Abstract
 Introduction
 Methods
 Results
 Discussion
 Conclusion
 References
 
Data were extracted from the ICU database and hospital charts with the approval of the Research Ethics Board. A multidisciplinary committee was formed with representation from nursing (management, education, and bedside), respiratory therapy, pharmacy, database, and medicine, to design and implement a multifaceted evidenced based approach to VAP prevention.

Standard diagnostic criteria for VAP based upon Center for Disease Control guidelines were first established. Each VAP was diagnosed by a staff intensivist using standard clinical diagnostic criteria:7

- new and persistent (> 48 hr) pulmonary infiltrates on x-ray;
- fever > 38.5°C or < 35°C without other apparent source;
- leucocytosis > 109·L–1 or < 3 x 109·L–1;
- impaired gas exchange;
- change in sputum quality ± positive sputum culture;
- bronchoalveolar lavage cultures in some patients.

Our data recording system was first improved by having the occurrence of cases captured by one or both duty intensivists and by independent chart review by a health care analyst. The presence of VAP was recorded in the ICU database which records data (Apache II scores, therapies including ventilation, complications, etc.) about all patients in the ICU from the clinical record cards used by the two ICU physicians on service each day, and by daily review of charts and patient problem cards by health care analysts. Baseline data were collected over six months while the protocol was being assembled, and the collected data confirmed our impression that this was indeed a common problem in our multidisciplinary adult ICU.

The protocol was introduced into clinical practice in January 2000, and incorporated measures shown by various levels of evidence to reduce the frequency of VAP.5 It included both an educational program and a preventative program:

1) An educational program
This was prepared for physicians, nurses, respiratory therapists, pharmacists, to raise the awareness of all personnel about the problem. This included entering a chapter in the residents’ orientation book to explain the protocol and its rationale, and its components were taught and reviewed at the bedside as they arose during rounds and teaching sessions. In addition, we undertook the education of the approximately 120 nurses working in the ICU by the two nurse educators using the following initiatives:

- in-services highlighting the etiology of VAP and the main aspects of the protocol;
- nurse educators plus a core group of ICU nurses were on-call for nurses requesting assistance with feeding tube insertion;
- a poster describing the technique for feeding tube insertion was posted at each bedside for accessible reference;
- a VAP reference binder containing in-service material was located within the ICU;
- an information ‘blitz’ at the bedside was conducted frequently by the nurse educators;
- small group teaching sessions were held from time to time;
- posters to raise the awareness of VAP and the protocol were placed around the ICU;
- geometric models to improve awareness of the reality of the 30–45° angle for bed head elevation were made available throughout the ICU;
- the protocol was included in the orientation program for nurses joining the staff of the ICU.

2) A preventative program
A number of recommendations being used at the time of protocol implementation were emphasized to improve compliance. This included strict adherence to guidelines for antibiotic therapy with pharmacy monitoring, to restrict use of these drugs to situations with clear indications, as previous exposure to antibiotics is an important risk factor for VAP.8

Emphasis was placed on strict hand hygiene techniques between patient contacts9 by physicians, nurses, respiratory therapists, pharmacists, by washing or alcohol hand cleanser.

Ventilator circuits10 were monitored regularly with removal of accumulated condensate and replaced weekly or when contaminated with secretions, blood, etc.

Nasogastric and endotracheal tubes were removed as soon as clinically feasible.11

Measures were used to avoid unplanned extubation (restraints, appropriate sedation, securing of the tube to the patient, etc.) and subsequent reintubation (with potential for aspiration), which is associated with an increased incidence of nosocomial pneumonia.12

Nasal intubation, which is associated with sinusitis and subsequent aspiration of infected secretions13 was avoided. Endotracheal tube cuff pressure was monitored to prevent leakage of secretions into the lower airway.14 Enteral or parenteral nutritional support,15 which is thought to reduce the occurrence of VAP, was emphasized.

Some practices supported by equivocal evidence were already being used, including heat and moisture exchange humidifiers,16 and closed in-line suctioning.17 We also used drugs which increase gastrointestinal motility, e.g., metoclopramide, domperidone, to encourage gastric emptying,18 in the presence of high gastric residual volumes (≥ 200 mL). Sedative and analgesic drugs were titrated to effect to avoid gastroparesis from the use of excessive doses.

Recommendations introduced with the protocol included ventilating patients with stable hemodynamics in a semi-recumbent (30–45°) head-up position, to reduce the aspiration of gastric secretions.19,20 Gastric fluid volume was minimized to reduce the potential for regurgitation and aspiration of stomach contents:11

  1. Enteral nutrition was commenced as soon as possible after ICU admission using small-bore transpyloric feeding tubes directed into the small bowel rather than being left in the stomach, with radiological confirmation of tube position safely in the esophagus (midline just below the carina) before being advanced into the stomach and through the pylorus.21
  2. If gastric feeding was used, gastric residual volumes were monitored to warn of intragastric fluid retention and potential overdistension,11 which was treated with motility drugs, suction, and a reduced rate of feeding.

Stress-ulcer prophylaxis was restricted to high-risk patients,22 to reduce bacterial colonization of the stomach and subsequent colonization of the upper respiratory tract followed by aspiration and pneumonia; it was discontinued once patients were fed at their optimal rate. Mouthcare was provided with chlorhexidine mouthwash (0.12% Apo Chlorhexidine, Apotex Inc.),23 15 mL twice daily while intubated.

Both formal and informal audits were used to monitor compliance and to identify barriers to implementation for specific attention.

Statistical analysis
Patient numbers admitted from each service, actual mortality and predicted mortality rates before and after protocol implementation were compared using Chi-square tests. ICU lengths of stay and Apache scores were compared using t tests. VAP incidence rates per 1,000 ventilator days were compared using a large-sample one-sample binomial test. P < 0.05 was considered statistically significant.


    Results
 TOP
 Abstract
 Introduction
 Methods
 Results
 Discussion
 Conclusion
 References
 
The introduction of the VAP prevention protocol in January 2000 reduced the incidence of VAP from a rate of 94 per year in the six-month baseline data collection period before protocol introduction to an average of 51.3 per year over the three years afterwards (Table IIGo, FigureGo). This corresponds to an incidence of 26.7 per 1,000 ventilator days before and 12.5 per 1,000 ventilator days after protocol introduction (P < 0.0001). The ICU length of stay of patients who developed VAP was longer than the average for all patients (18.1 ± 16.6 vs 4.8 ± 6.8 days respectively before implementation, 22.6 ± 17.0 for VAP patients vs 5.8 ± 8.3 days respectively after implementation, P < 0.0001). The hospital mortality predicted from Apache II scores and diagnostic categories for all patients, increased from 29.6% before to 35.1% after (P = 0.0052). The predicted hospital mortality of VAP patients (36.7% before, 39.4% after) was unchanged (P = 0.755; Table IIGo).


View this table:
[in this window]
[in a new window]
 
TABLE II Data for VAP patients
 


View larger version (93K):
[in this window]
[in a new window]
 
FIGURE The bar graph indicates the incidence of ventilator-associated pneumonia (VAP) per 1000 ventilator days in six-month periods during the audit. Mean ± SD refer to the periods before and after the introduction of the preventative protocol. *P < 0.0001.

 
While the patient population mix did change during the time of the audit Table IGo, (P < 0.0001), there were significant reductions in the incidence of VAP overall (P < 0.0003) and within medical (P = 0.0148) and surgical (P = 0.0062) admission groups (but not medical sub-specialties (P = 0.118).


View this table:
[in this window]
[in a new window]
 
TABLE I Characteristics of ICU population during the study
 

    Discussion
 TOP
 Abstract
 Introduction
 Methods
 Results
 Discussion
 Conclusion
 References
 
Early onset VAP typically occurs within 48 to 96 hr after endotracheal intubation, and often results from aspiration during intubation.5,24 The organisms most frequently identified are Haemophilus influenzae and Streptococcus pneumoniae. Late onset VAP occurs more than 96 hr after endotracheal intubation, and is more frequently caused by antibiotic resistant pathogens, including Staphylococcus aureus, Pseudomonas aeroginosa, Acinetobacter species, Enterobacter species, and other gram negative organisms. Twenty to 40% of pneumonias are polymicrobial, and the presence of anaerobic organisms or fungi is variable.

The pathogenesis involves bacterial colonization of the upper airways followed by aspiration of contaminated secretions into the lower airway.25 Contributing factors include the presence of a nasogastric tube which predisposes to reflux of gastric contents. Instrumentation of the airway with an endotracheal tube or tracheostomy interferes with coughing and mucociliary function, thereby facilitating colonization of the tracheobronchial tree and aspiration of contaminated secretions. Contaminated secretions pool above the endotracheal tube cuff from where they are difficult to aspirate by suction, but may leak past the cuff into the lower respiratory tract. The cough reflex is suppressed by sedation used to promote tolerance of the endotracheal tube. The ventilator circuit and other respiratory therapy equipment may be contaminated with bacteria from attendants or from the patient’s secretions. Elevation of gastric pH by drugs used for prophylaxis against gastrointestinal bleeding promotes colonization of the stomach with organisms from the intestines. Compromise of the immune system impairs the ability of the patient to resist infection. Previous antibiotic therapy disturbs the normal bacterial flora of the patient and promotes the development of resistant organisms.

The introduction of a VAP prevention protocol requires a multidisciplinary approach and buy-in from all parties. Individuals may be asked to change longstanding practices, and this requires explanation, encouragement, and reinforcement. The large number of involved individuals (nurses, respiratory technicians, etc.), increases the challenge for education.

The modalities included in our protocol are consistent with the guidelines of the Canadian Critical Care Society26 and the American Association of Critical Care Nurses.27 Many of the measures were already in place and would be considered good practice for other reasons, but were included to emphasize the multifaceted approach to the problem and they are no less important than the new modalities introduced. The educational program emphasized the importance of these measures to improve compliance and effectiveness. The key new modalities introduced were transpyloric feeding, elevation of the head of the bed to 30 to 45°, and mouth-care with chlorhexidine mouthwash.

Transpyloric feeding also accelerates the achievement of successful enteral feeding. This modality is also supported by the Canadian Clinical Practice Guidelines for Nutrition Support In Mechanically Ventilated Critically Ill Adult Patients.28 We developed a technique for the safe insertion of enteral feeding tubes by the bedside nurse, with a chest x-ray taken to confirm esophageal placement (feeding tube tip in the midline below the carina) before advancement and manipulation through the pylorus. This was successful in 60 to 70% of patients, the remainder requiring fluoroscopic placement.

Elevation of the head of the bed to 30–45° was the modality most challenging to achieve good compliance, requiring repeated educational efforts and in-services, spot checks with focused education, and the use of geometric models of the target angles. Chlorhexidine 0.12% mouthwash 15 mL was applied in the mouth twice daily while the patient was intubated to reduce oral bacterial flora.

One difficulty with this multifaceted approach is that it is not possible to determine the relative importance of the specific modalities of the protocol. The low cost and risk, and other advantages of some modalities, reduce the importance of this disadvantage. Several new modalities were introduced, while increased compliance with existing modalities was encouraged.

Other modalities may be considered for incorporation into our protocol in the future. Continuous aspiration of subglottic secretions that pool above the inflated endotracheal tube cuff has been shown to reduce the incidence and delay the onset of pneumonia.29 An evaluation of endotracheal tubes designed for this purpose was begun, but the tubes were withdrawn by the manufacturer because of technical problems with their use. Rotation therapy30 is not available because of cost considerations. The role of standardized diagnostic criteria including bronchoalveolar lavage sampling and quantitative cultures has yet to be established.

During the time of the audit, vascular surgery (November 2000), trauma, and neurosurgery (June 2001) were transferred away from, and oncology (June 2001), and thoracic surgery moved to the General Campus (June 2002). The reduced incidence of VAP in each admitting service group (Table IIGo) suggests that the findings were not a result of the change in patient population. Average Apache II scores increased slightly during the audit, indicating that while some of the patient diagnoses changed with the changing patient population, the average patient acuity remained high. Both the hospital mortality predicted from Apache II scores and patient diagnoses, and the actual hospital mortality of these patients increased. These are further indications that the reduction in incidence of VAP was not as a result of the presence of less critically ill patients in the ICU population.

Our study did not incorporate a method to evaluate costs attributable to VAP in our ICU. However, the financial burden of VAP has been assessed in several other studies, and estimated costs for increased ICU and hospital stay, antibiotics and other medications, etc., range from US $5,000 to $15,0003133 per episode.


    Conclusion
 TOP
 Abstract
 Introduction
 Methods
 Results
 Discussion
 Conclusion
 References
 
We conclude that adherence to simple and effective measures as described in this protocol significantly reduces the incidence of VAP. The protocol was inexpensive and effective, and has produced large estimated savings in ICU patient days and costs. Implementation and maintenance require a multidisciplinary approach, with buy-in from all team members, and ongoing monitoring, education, and feedback to the participants.


    Acknowledgments
 
We acknowledge the assistance of Dr. Paul Hébert in the preparation of this manuscript, Jennifer Clinch with statistical analysis, and the support and cooperation of the medical, nursing, pharmacy, and respiratory personnel at the General Campus ICU, without whose collaboration this project would not have been possible.

This work has been presented in part as poster presentations at the Canadian Anesthesologists’ Society meeting in Ottawa in 2003, the Toronto Critical Care Medicine Symposium in 2003, and the Canadian Critical Care Nurses Association "Dynamics" meeting in 2001.


    Footnotes
 
Accepted for publication June 3, 2004. Revision accepted February 15, 2005.


    References
 TOP
 Abstract
 Introduction
 Methods
 Results
 Discussion
 Conclusion
 References
 
1 Craven DE, Kunches LM, Lichtenberg DA, et al. Nosocomial infection and fatality in medical and surgical intensive care unit patients. Arch Intern Med 1988; 148: 1161–8.[Abstract]

2 Torres A, Aznar E, Gatell JM, et al. Incidence, risk, and prognostic factors of nosocomial pneumonia in mechanically ventilated patients. Am Rev Respir Dis 1990; 142: 523–8.[Medline]

3 Kollef MH, Silver P, Murphy DM, Trovillion E. The effect of late-onset ventilator-associated pneumonia in determining patient mortality. Chest 1995; 108: 1655–62.[Abstract/Free Full Text]

4 Heyland DK, Cook DJ, Griffith L, Keenan SP, Brun-Buisson C. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. Canadian Critical Care Trials Group. Am J Respir Crit Care Med 1999; 159: 1249–56.[Abstract/Free Full Text]

5 Kollef MH. The prevention of ventilator-associated pneumonia. N Engl J Med 1999; 340: 627–34.[Free Full Text]

6 Heyland DK, Cook DJ, Dodek PM. Prevention of ventilator-associated pneumonia: current practice in Canadian intensive care units. J Crit Care 2002; 17: 161–7.[Medline]

7 Anonymous. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies. A consensus statement. Am J Respir Crit Care Med 1995; 153: 1711–25.

8 Goldmann DA, Weinstein RA, Wenzel RP, et al. Strategies to prevent and control the emergence and spread of antimicrobial resistant microorganisms in hospitals. A challenge to hospital leadership. Workshop to Prevent and Control the Emergence and Spread of Antimicrobial Microorganisms in Hospitals. JAMA 1996; 275: 234–40.[Abstract]

9 Doebbeling BN, Stanley GL, Sheetz CT, et al. Comparative efficacy of alternative hand-washing agents in reducing nosocomial infections in intensive care units. N Engl J Med 1992; 327: 88–93.[Abstract]

10 Kollef MH, Shapiro SD, Fraser VJ, et al. Mechanical ventilation with or without 7-day circuit changes. A randomized controlled trial. Ann Intern Med 1995; 123: 168–74.[Abstract/Free Full Text]

11 Tablan OC, Anderson LJ, Arden NH, Breiman RF, Butler JC, McNeil MM. Guideline for prevention of nosocomial pneumonia. The Hospital Infection Control Practices Advisory Committee. Centres for Disease Control and Prevention. Infect Control Hosp Epidemiol 1994; 15: 587–627.[Medline]

12 Torres A, Gatell JM, Aznar E, et al. Re-intubation increases the risk of nosocomial pneumonia in patients needing mechanical ventilation. Am J Respir Crit Care Med 1995; 152: 137–41.[Abstract]

13 Holzapfel L, Chevret S, Madinier G, et al. Influence of long-term oro- or nasotracheal intubation on nosocomial maxillary sinusitis and pneumonia: results of a prospective, randomized, clinical trial. Crit Care Med 1993; 21: 1132–8.[Medline]

14 Rello J, Sonora R, Jubert P, Artigas A, Rue M, Valles J. Pneumonia in intubated patients: role of respiratory airway care. Am J Respir Crit Care Med 1996; 154: 111–5.[Abstract]

15 Nierderman MS, Mantovani R, Schoch P, Papas J, Fein AM. Patterns and routes of tracheobronchial colonization in mechanically ventilated patients. The role of nutritional status in colonization of the lower airway by Pseudomonas species. Chest 1989; 95: 155–61.[Abstract/Free Full Text]

16 Kollef MH, Shapiro SD, Boyd V, et al. A randomized clinical trial comparing an extended-use hygroscopic condenser humidifier with heated-water humidification in mechanically ventilated patients. Chest 1998; 113: 759–67.[Abstract/Free Full Text]

17 Combes P, Fauvage B, Oleyer C. Nosocomial pneumonia in mechanically ventilated patients, a prospective randomised evaluation of the Stericath closed suctioning system. Intensive Care Med 2000; 26: 878–82.[Medline]

18 Yavagal DR, Karnad DR, Oak JL. Metoclopramide for preventing pneumonia in critically ill patients receiving enteral tube feeding: a randomized controlled trial. Crit Care Med 2000; 28: 1408–11.[Medline]

19 Torres A, Serra-Batlles J, Ros E, et al. Pulmonary aspiration of gastric contents in patients receiving mechanical ventilation: the effect of body position. Ann Intern Med 1992; 116: 540–3.

20 Drakulovic MB, Torres A, Bauer TT, Nicolas JM, Nogue S, Ferrer M. Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: a randomised trial. Lancet 1999; 354: 1851–8.[Medline]

21 Kortbeek JB, Haigh PL, Doig C. Duodenal versus gastric feeding in ventilated blunt trauma patients: a randomized controlled trial. J Trauma 1999; 46: 992–8.[Medline]

22 Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med 1994; 330: 377–81.[Abstract/Free Full Text]

23 DeRiso AJ II, Ladowski JS, Dillion TA, Justice JW, Peterson AC. Chlorhexidine gluconate 0.12% oral rinse reduces the incidence of total nosocomial respiratory infection and nonprophylactic systemic antibiotic use in patients undergoing heart surgery. Chest 1996; 109: 1556–61.[Abstract/Free Full Text]

24 Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165: 867–903.[Abstract/Free Full Text]

25 Craven DE, Steger KA. Epidemiology of nosocomial pneumonia. New perspectives on an old disease. Chest 1995; 108(Suppl): 1S–16S.[Medline]

26 Dodek P, Keenan S, Cook D, et al. Evidenced-based clinical practice guideline for the prevention of ventilator-associated pneumonia. Canadian Critical Care Trials Group and the Canadian Critical Care Society. Ann Intern Med 2004; 141: 305–13.[Abstract/Free Full Text]

27 McKay CA, Speers M. AACN practice alert. Ventilator associated pneumonia. AACN NEWS, 2004; 21: 2. Available from URL; www.AACN.org.

28 Heyland DK, Dhaliwal R, Drover JW, Gramlich L, Dodek P. Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients. Canadian Critical Care Clinical Practice Guidelines Committee. JPEN J Parenter Enteral Nutr 2003; 27: 355–73.[Abstract/Free Full Text]

29 Valles J, Artigas A, Rello J, et al. Continuous aspiration of subglottic secretions in preventing ventilator-associated pneumonia. Ann Intern Med 1995; 122: 179–86.[Abstract/Free Full Text]

30 Fink MP, Helsmoortel CM, Stein KL, Lee PC, Cohn SM. The efficacy of an oscillating bed in the prevention of lower respiratory tract infection in critically ill victims of blunt trauma. A prospective study. Chest 1990; 97: 132–7.[Abstract/Free Full Text]

31 Boyce JM, Potter-Bynoe G, Dziobek L, Solomon SL. Nosocomial pneumonia in Medicare patients. Hospital costs and reimbursement patterns under the prospective payment system. Arch Intern Med 1991; 151: 1109–14.[Abstract]

32 Shorr AF, O’Malley PG. Continuous subglottic suctioning for the prevention of ventilator-associated pneumonia. Potential economic implications. Chest 2001; 119: 228–35.[Abstract/Free Full Text]

33 Warren DK, Shukla SJ, Olsen MA, et al. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med 2003; 31: 1312–7.[Medline]




This article has been cited by other articles:


Home page
J Antimicrob ChemotherHome page
R. G. Masterton, A. Galloway, G. French, M. Street, J. Armstrong, E. Brown, J. Cleverley, P. Dilworth, C. Fry, A. D. Gascoigne, et al.
Guidelines for the management of hospital-acquired pneumonia in the UK: Report of the Working Party on Hospital-Acquired Pneumonia of the British Society for Antimicrobial Chemotherapy
J. Antimicrob. Chemother., July 1, 2008; 62(1): 5 - 34.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
A. P. Wheeler
Recent Developments in the Diagnosis and Management of Severe Sepsis
Chest, December 1, 2007; 132(6): 1967 - 1976.
[Abstract] [Full Text] [PDF]


Home page
Canadian J. AnesthesiaHome page
T. Sinuff, K. W. Eva, M. Meade, P. Dodek, D. Heyland, and D. Cook
Clinical practice guidelines in the intensive care unit: a survey of Canadian clinicians' attitudes: [Guide de pratique clinique dans les unites de soins intensifs : un sondage sur les attitudes des cliniciens canadiens]
Can J Anesth, September 1, 2007; 54(9): 728 - 736.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
R. Omrane, J. Eid, M. M Perreault, H. Yazbeck, D. Berbiche, A. Gursahaney, and Y. Moride
Impact of a Protocol for Prevention of Ventilator-Associated Pneumonia
Ann. Pharmacother., September 1, 2007; 41(9): 1390 - 1396.
[Abstract] [Full Text] [PDF]


Home page
Canadian J. AnesthesiaHome page
A. D. Baxter and S. Kanji
Protocol implementation in anesthesia: beta-blockade in non-cardiac surgery patients: [Application d'un protocole en anesthesie : les beta-bloquants chez les patients en chirurgie non cardiaque]
Can J Anesth, February 1, 2007; 54(2): 114 - 123.
[Abstract] [Full Text] [PDF]


Home page
Canadian J. AnesthesiaHome page
P. Dodek
Improving patient safety in critical care: big challenge, exciting opportunity/L'amelioration de la securite des patients a l'unite des soins intensifs : un grand defi, une occasion stimulante
Can J Anesth, May 1, 2005; 52(5): 459 - 462.
[Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Résumé de cet Article
Right arrow Full Text (PDF)
Right arrow Submit a scholarly reply
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baxter, A. D.
Right arrow Articles by Jansen, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baxter, A. D.
Right arrow Articles by Jansen, O.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS